The FDA approved an Impel NeuroPharma migraine treatment, a nasal spray intended to bring pain relief more quickly than drugs administered in other ways. It marks the first approval for the Seattle company, which has developed a proprietary nasal delivery technology.
The five life sciences IPOs this week continues the steady march companies are making to the public markets this year. This week's activity follows a first quarter that Renaissance Capital calculates was the busiest for newly public companies since 2000. Healthcare IPOs continued to dominate the stock offerings.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Seattle-based Impel NeuroPharma has attracted investment from 3M's venture arm. It's developing an inhaled drug delivery product that sends medication straight to the brain and CNS.